Home DNA Damage/DNA Repair MTH1 inhibitor (S)-crizotinib

research use only

(S)-crizotinib MTH1 inhibitor

Cat.No.S7505

(S)-crizotinib, the (S)-enantiomer of crizotinib, is a potent MTH1 (NUDT1) inhibitor with IC50 of 72 nM in a cell-free assay.
(S)-crizotinib MTH1 inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 450.34

Jump to

Quality Control

Batch: Purity: 99.99%
99.99

Solubility

In vitro
Batch:

DMSO : 45 mg/mL (99.92 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 31 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 450.34 Formula

C21H22Cl2FN5O

 Storage (From the date of receipt)
CAS No. 1374356-45-2 Download SDF Storage of Stock Solutions

Synonyms N/A SMILES CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Features
MTH1 (NUDT1)- selective inhibitor.
Targets/IC50/Ki
NUDIX1
MTH1
(Cell-free assay)
72 nM
In vitro
(S)-crizotinib disrupts nucleotide pool homeostasis via MTH1 inhibition, induces an increase in DNA single-strand breaks, and activates DNA repair in human colon carcinoma cells.
Kinase Assay
MTH1 catalytic assay
Half-maximal inhibitory concentrations (IC50) are determined using a luminescence-based assay with some minor modifications. Briefly, serial dilutions of compounds are dissolved in assay buffer (100 mM Tris-acetate pH 7.5, 40 mM NaCl and 10 mM Mg(OAc)2 containing 0.005% Tween-20 and 2 mM dithiothreitol (DTT). Upon addition of MTH1 recombinant protein (final concentration 2 nM), plates are incubated on a plate shaker for 15 min at room temperature. After addition of the substrate dGTP (final concentration 100 µM), 8-oxo-dGTP (final concentration 13.2 µM), or 2-OH-dATP (final concentration 8.3 µM) the generation of pyrophosphate (PPi) as a result of nucleotide triphosphate hydrolysis by MTH1 is monitored over a time course of 15 min using the PPi Light Inorganic Pyrophosphate Assay kit. IC50 values are determined by fitting a dose-response curve to the data points using nonlinear regression analysis using the GraphPad Prism software.
In vivo
(S)-Crizotinib (50 mg/kg, orally, daily) impairs tumor growth in an SW480 colon carcinoma xenograft model.
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2023-02-21)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05725200 RECRUITING
Metastatic Colorectal Cancer
Oslo University Hospital
 2022-09-27 PHASE2
NCT02201992 ACTIVE_NOT_RECRUITING
ALK Gene Rearrangement; ALK Gene Translocation; ALK Positive; Stage IB Non-Small Cell Lung Carcinoma AJCC v7; Stage II Non-Small Cell Lung Cancer AJCC v7; Stage IIA Non-Small Cell Lung Carcinoma AJCC v7; Stage IIB Non-Small Cell Lung Carcinoma AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7
ECOG-ACRIN Cancer Research Group
 2015-03-23 PHASE3
NCT07804186 RECRUITING
Uveal Melanoma
IDEAYA Biosciences
 2026-09 PHASE3
NCT07560410 NOT_YET_RECRUITING
Bone Cancer
China Medical University Hospital
 2026-05-15 PHASE1; PHASE2
NCT06564324 RECRUITING
Non Small Cell Lung Cancer
Nuvation Bio Inc.
 2024-11-27 PHASE3
NCT05160922 ACTIVE_NOT_RECRUITING
NSCLC; ALCL; IMT
Pfizer
 2021-12-27 PHASE4

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Could you tell me whether this product represents the pure R-form of it, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

Answer:
Our S1068 Crizotinib is R enantiomer, and S7505 is S enantiomer. Normally, it refers to the R enantiomer.